Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Georg Kralidis"'
Autor:
Hiltrud Liedgens, Annette Christoph, Georg Kralidis, Donald M. Bushnell, Mona L. Martin, Mariёlle Eerdekens
Publikováno v:
Current medical research and opinion. 36(5)
Objective: The Patient Assessment for Low Back Pain–Symptoms (PAL-S) and the Patient Assessment for Low Back Pain–Impacts (PAL-I) were developed to incorporate patient perspective of treatment bene...
Autor:
Ingo Sabatschus, Jiří Létal, E. Dietlind Koch, Sofia Kapanadze, Marie-Henriette Eerdekens, Georg Kralidis, Sam H Ahmedzai
Publikováno v:
Journal of pain and symptom management. 58(3)
Context Pain is one of the most prevalent symptoms associated with cancer. Strong opioids are commonly used in the analgesic management of the disease, but carry the risk of severe side effects. Cebranopadol is a first-in-class drug candidate, combin
Publikováno v:
Pharmaceutical statistics. 18(2)
MCP-Mod has been proposed as analysis method for investigating the dose-response (DR) relationship and dose finding in clinical Phase II trials. The original methodology as well as several generalizations are well accepted by Health Authorities. In t
Autor:
Gisela Volkers, Marie-Henriette Eerdekens, Erika Dietlind Koch, Georg Kralidis, Winfried Meissner, Sofia Kapanadze, Sam H Ahmedzai
Publikováno v:
European journal of pain (London, England). 23(3)
Background Cancer-related pain is a growing health problem given the increasing life expectancy of cancer patients. Opioids are commonly used to treat cancer-related pain, but carry the risk of severe side effects, limiting their use. Cebranopadol is
Autor:
Peggy Norton, William D. Steers, Richard J. Millard, Georg Kralidis, Karin Glavind, Christopher R. Chapple, Paul Abrams
Publikováno v:
Chapple, C, Steers, W, Norton, P, Millard, R, Kralidis, G, Glavind, K & Abrams, P 2005, ' A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M-3 selective receptor antagonist, in the treatment of overactive bladder ', B J U International
, vol. 95, no. 7, pp. 993-1001 .
, vol. 95, no. 7, pp. 993-1001 .
An international group of authors present a pooled analysis of data from their phase III multicentre double-blind clinical trials in patients with overactive bladder, which evaluated the efficacy, tolerability and safety of darifenacin. They found th
Publikováno v:
BJU international. 95(4)
OBJECTIVES To evaluate the efficacy, tolerability and safety of a flexible-dosing strategy with darifenacin, an M3-selective receptor antagonist, in patients with symptoms of overactive bladder (OAB). PATIENTS AND METHODS In this multicentre double-b
Publikováno v:
Foote, J, Glavind, K, Kralidis, G & Wyndaele, J J 2005, ' Treatment of overactive bladder in the older patient: Pooled analysis of three phase III studies of darifenacin, an M-3 selective receptor antagonist ', European Urology, vol. 48, no. 3, pp. 471-477 .
European urology
European urology
Aim: To evaluate the efficacy, tolerability and safety of darifenacin, an M-3 selective receptor antagonist, in the subgroup of older patients from a pooled analysis of three phase III, multicentre, randomized, double-blind clinical trials in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4d8c880e3aefded12b02e265d13b46d
https://pure.au.dk/portal/da/publications/treatment-of-overactive-bladder-in-the-older-patient-pooled-analysis-of-three-phase-iii-studies-of-darifenacin-an-m3-selective-receptor-antagonist(95ca5970-aae5-11da-bee9-02004c4f4f50).html
https://pure.au.dk/portal/da/publications/treatment-of-overactive-bladder-in-the-older-patient-pooled-analysis-of-three-phase-iii-studies-of-darifenacin-an-m3-selective-receptor-antagonist(95ca5970-aae5-11da-bee9-02004c4f4f50).html
Autor:
Friedhelm Schreiter, Roberto Olianas, Georg Kralidis, Margit Fisch, Matthias Heitz, Thomas M. Kessler
Publikováno v:
The Journal of urology. 170(3)
We assessed the long-term results of surgery for urethral stricture by statistical methods using guidelines for survival analysis.Of the 267 patients who underwent surgery for urethral strictures between March 1993 and December 1999, 238 (89%) were f